COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Fundamental Analysis

NASDAQ:COLL • US19459J1043

45 USD
-0.18 (-0.4%)
At close: Feb 20, 2026
45 USD
0 (0%)
After Hours: 2/20/2026, 4:12:37 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall COLL gets a fundamental rating of 6 out of 10. We evaluated COLL against 191 industry peers in the Pharmaceuticals industry. COLL scores excellent on profitability, but there are some minor concerns on its financial health. COLL may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make COLL a good candidate for value investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year COLL was profitable.
  • In the past year COLL had a positive cash flow from operations.
  • COLL had positive earnings in 4 of the past 5 years.
  • In the past 5 years COLL always reported a positive cash flow from operatings.
COLL Yearly Net Income VS EBIT VS OCF VS FCFCOLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • COLL's Return On Assets of 3.64% is amongst the best of the industry. COLL outperforms 84.29% of its industry peers.
  • COLL's Return On Equity of 21.27% is amongst the best of the industry. COLL outperforms 91.10% of its industry peers.
  • With an excellent Return On Invested Capital value of 9.10%, COLL belongs to the best of the industry, outperforming 88.48% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for COLL is in line with the industry average of 12.64%.
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROIC 9.1%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
COLL Yearly ROA, ROE, ROICCOLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

  • The Profit Margin of COLL (7.72%) is better than 82.72% of its industry peers.
  • COLL's Profit Margin has declined in the last couple of years.
  • COLL has a better Operating Margin (20.74%) than 89.01% of its industry peers.
  • COLL's Operating Margin has improved in the last couple of years.
  • COLL's Gross Margin of 57.22% is fine compared to the rest of the industry. COLL outperforms 68.59% of its industry peers.
  • In the last couple of years the Gross Margin of COLL has grown nicely.
Industry RankSector Rank
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
COLL Yearly Profit, Operating, Gross MarginsCOLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), COLL is creating some value.
  • Compared to 1 year ago, COLL has less shares outstanding
  • COLL has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, COLL has an improved debt to assets ratio.
COLL Yearly Shares OutstandingCOLL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
COLL Yearly Total Debt VS Total AssetsCOLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • COLL has an Altman-Z score of 1.45. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
  • COLL's Altman-Z score of 1.45 is in line compared to the rest of the industry. COLL outperforms 58.12% of its industry peers.
  • COLL has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as COLL would need 2.79 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 2.79, COLL belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
  • COLL has a Debt/Equity ratio of 2.71. This is a high value indicating a heavy dependency on external financing.
  • COLL has a worse Debt to Equity ratio (2.71) than 81.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Altman-Z 1.45
ROIC/WACC0.99
WACC9.16%
COLL Yearly LT Debt VS Equity VS FCFCOLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • COLL has a Current Ratio of 1.36. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of COLL (1.36) is worse than 74.35% of its industry peers.
  • COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • COLL has a worse Quick ratio (1.27) than 69.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.27
COLL Yearly Current Assets VS Current LiabilitesCOLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.73%, which is quite impressive.
  • The Earnings Per Share has been growing by 154.78% on average over the past years. This is a very strong growth
  • COLL shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.34%.
  • Measured over the past years, COLL shows a quite strong growth in Revenue. The Revenue has been growing by 16.31% on average per year.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%

3.2 Future

  • Based on estimates for the next years, COLL will show a small growth in Earnings Per Share. The EPS will grow by 0.05% on average per year.
  • The Revenue is expected to grow by 4.61% on average over the next years.
EPS Next Y18.1%
EPS Next 2Y12.08%
EPS Next 3Y-0.6%
EPS Next 5Y0.05%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y4.61%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
COLL Yearly Revenue VS EstimatesCOLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
COLL Yearly EPS VS EstimatesCOLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6 8

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 6.26, which indicates a rather cheap valuation of COLL.
  • COLL's Price/Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 95.81% of the companies in the same industry.
  • COLL's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.99.
  • The Price/Forward Earnings ratio is 5.55, which indicates a rather cheap valuation of COLL.
  • 94.76% of the companies in the same industry are more expensive than COLL, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. COLL is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 6.26
Fwd PE 5.55
COLL Price Earnings VS Forward Price EarningsCOLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 97.91% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, COLL is valued cheaply inside the industry as 96.86% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.92
EV/EBITDA 4.74
COLL Per share dataCOLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of COLL may justify a higher PE ratio.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y12.08%
EPS Next 3Y-0.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • COLL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (2/20/2026, 4:12:37 PM)

After market: 45 0 (0%)

45

-0.18 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners120.33%
Inst Owner Change-4.46%
Ins Owners1.42%
Ins Owner Change2.01%
Market Cap1.42B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.67
Price Target54.23 (20.51%)
Short Float %15.42%
Short Ratio10.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)9.25%
PT rev (3m)19.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.38%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.92%
Valuation
Industry RankSector Rank
PE 6.26
Fwd PE 5.55
P/S 1.88
P/FCF 4.92
P/OCF 4.89
P/B 5.18
P/tB N/A
EV/EBITDA 4.74
EPS(TTM)7.19
EY15.98%
EPS(NY)8.1
Fwd EY18.01%
FCF(TTM)9.15
FCFY20.34%
OCF(TTM)9.2
OCFY20.45%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.35
PEG (5Y)N/A
Graham Number37.5
Profitability
Industry RankSector Rank
ROA 3.64%
ROE 21.27%
ROCE 13.6%
ROIC 9.1%
ROICexc 12.09%
ROICexgc N/A
OM 20.74%
PM (TTM) 7.72%
GM 57.22%
FCFM 38.21%
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.71
Debt/FCF 2.79
Debt/EBITDA 1.94
Cap/Depr 0.72%
Cap/Sales 0.21%
Interest Coverage 2.17
Cash Conversion 75.92%
Profit Quality 495.01%
Current Ratio 1.36
Quick Ratio 1.27
Altman-Z 1.45
F-Score7
WACC9.16%
ROIC/WACC0.99
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y18.1%
EPS Next 2Y12.08%
EPS Next 3Y-0.6%
EPS Next 5Y0.05%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year24.13%
Revenue Next 2Y13.42%
Revenue Next 3Y4.47%
Revenue Next 5Y4.61%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year157.27%
EBIT Next 3Y28.14%
EBIT Next 5Y19.55%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%

COLLEGIUM PHARMACEUTICAL INC / COLL FAQ

What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

ChartMill assigns a fundamental rating of 6 / 10 to COLL.


What is the valuation status for COLL stock?

ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.


What is the profitability of COLL stock?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.


Can you provide the financial health for COLL stock?

The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.